Ulcerative colitis practice guidelines in adults

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue 2, 2012, Pages 103-106

  Eugene C ^a  

^a Clinique Saint Louis   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; 6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; OLSALAZINE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COLITIS; COLON RESECTION; CORTICOSTEROID THERAPY; CROHN DISEASE; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; ILEITIS; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; META ANALYSIS; MONOTHERAPY; NEPHROTOXICITY; PRACTICE GUIDELINE; RELAPSE; REMISSION; STEROID THERAPY; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; WOUND HEALING;

ADULT; COLITIS, ULCERATIVE; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84858624589     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.11.001     Document Type: Article

References (15)

1. Kornblut A., Sachar D.B. Ulcerative colitis practice guidelines in adults Commentary (part 2). Am J Gastroenterol 2010, 105:501-523. the Practice Parameters Committee of the American College of Gastroenterology.
2. Travis S.P.L., Stange E.F., Lémann M., Oresland T., Benelman W.A., Chowers Y., et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008, 2:24-62.
3. Ford A.C., Achkar J.P., Khan K.J., Kane S.V., Talley N.J., Marshall J.K., et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:601-616.
4. Talley N.J., Abreu M.T., Achkar J.P., Bernstein C.N., Dubinsky M.C., Hanauer S.B., et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011, 106:S2-S25.
5. Lichtenstein G.R., Ramsey D., Rubin D.T. Randomised clinical trial: delayed-release oral mesalazine 4.8g/day vs 2.4g/day in endoscopic mucosal healing-ASCEND I and II combined analysis. Aliment Pharmacol Ther 2011, 33:672-678.
6. Lichtenstein G.R., Gordon G.L., Zakko S., Murthy U., Sedghi S., Pruitt R., et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis-a 6-month placebo-controlled trial. Aliment Pharmacol Ther 2010, 32:990-999.
7. Kruis W., Jonaitis L., Prokonietks J., Mikhailova T.L., Horynski L., Batovsky M., et al. Randomised trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ucerative colitis. Aliment Pharmacol Ther 2011, 33:313-322.
8. Ford A.C., Bernstein C.N., Khan K.J., Abreu M.T., Marshall J.K., Talley N.J., et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:590-599.
9. Khan K.J., Dubinsky M.C., Ford A.C., Ullman T.A., Talley N.J., Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011, 106:630-642.
10. Ford A.C., Sandborn W.J., Khan K.J., Hanauer S.B., Talley N.J., Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:644-659.
11. Reinisch W., Sandborn W.J., Hommes D.W., D'Haens G., Hanauer S., Schreiber S., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomized controlled trial. Gut 2011, 60:780-787.
12. Reinisch W., Sandborn W.J., Rutgeerts P., Feagan B.G., Rachmilewitz D., Hanauer S.B., et al. Long-term infliximab therapy for ulcerative colitis: the ACT-1ans -2 extension studies. Inflamm Bowel Dis 2011, 10.1002/ibd.21697.
13. Gies N., Kroeker K.I., Wong K., Fedorak R.N. Treatment of ulcerative colitis with adalumimab or infliximab: long term follow-up or a single center cohort. Aliment Pharmacol Ther 2010, 32:522-528.
14. Panaccione R, Ghosh S, Middleton S, Velazquez JRM, Khalif I, Flint L, et al. Infliximab, azathioprine, or infliximab+azathioprine for treatment of moderate to severe ulcerative colitis.: the UC Success trial. Program and abstracts of Digestive Diseases Week 2011, may 7-10, 2011; Chicago, Illinois, Abstract 835.
15. Colombel J.F., Rutgeerts P., Reinisch W., Esser D., Wang Y., Lang Y., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141:1194-1201.